118 related articles for article (PubMed ID: 38266771)
1. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
3. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
4. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
5. A functional genetic screen for metabolic proteins unveils GART and the
Cipolletti M; Leone S; Bartoloni S; Acconcia F
Front Endocrinol (Lausanne); 2023; 14():1129162. PubMed ID: 37143728
[TBL] [Abstract][Full Text] [Related]
6. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
9. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
[TBL] [Abstract][Full Text] [Related]
13. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
Huggins RJ; Greene GL
NPJ Breast Cancer; 2023 Nov; 9(1):96. PubMed ID: 38036546
[TBL] [Abstract][Full Text] [Related]
14. A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.
Cipolletti M; Bartoloni S; Busonero C; Parente M; Leone S; Acconcia F
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805656
[TBL] [Abstract][Full Text] [Related]
15. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
16. Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.
Bartoloni S; Leone S; Acconcia F
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32408555
[TBL] [Abstract][Full Text] [Related]
17. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
Front Chem; 2019; 7():602. PubMed ID: 31552220
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
19. The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.
Bartoloni S; Leone S; Pescatori S; Cipolletti M; Acconcia F
Mol Oncol; 2022 Oct; 16(19):3568-3584. PubMed ID: 36056637
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Acconcia F
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]